Management of patients with systemic autoimmune diseases with the active phase of chronic herpes simplex infection

  • I.G. Gaiduchok National Medical Institute in Lviv
  • Kh.O. Lishchuk-Yakymovych The Danylo Halytsky National Medical University in Lviv
Keywords: systemic autoimmune diseases, herpes simplex viruses, antiviral therapy

Abstract

Aim. To study the effectiveness of acyclovir in patients with systemic autoimmune diseases caused by active chronic herpes simplex 1/2 infection.

Material and Methods. Among 380 patients with systemic autoimmune diseases (systemic lupus erythematosus, systemic vasculitis, rheumatoid arthritis, psoriasis) in 45 (11.8%) patients was diagnosed active phase of chronic HSV1/2 infection with help of viral DNA identification by polymerase chain reaction. These patients received acyclovir in three courses with a one-month interval between them. The effectiveness of treatment was monitored before and after treatment with help of virus DNA results in three bioenvironments (blood, saliva and swab from the lesion), of general and specific IgM, IgG antibodies concentration; levels of IgE, cryoglobulins, circulating immune complexes, alpha-interferon, C3-component of complement, the number of lymphocytes populations/subpopulations and of activated cells.

Results and Discussion. After the treatment, it was fixed as significant decrease of specific IgM, IgG antibodies concentration as of the level of total IgE, cryoglobulins and cryofibrinogen. In addition it was observed as significant decreased level of alpha-interferon in the serum and saliva, as of the natural killers and number of lymphocytes, expressing the low-affinity receptor IL2 (CD25+) and lymphocytes with suppressive activity (CD4+25+). After the treatment it was observed by polymerase chain reaction a decrease of virus replication in 66.7% of cases.

Conclusions. The results of the study indicate, that the use of acyclovir for the treatment of active phase of chronic HSV 1/2-infection might contribute as to the decrease in the virus replication, reducing the viral load, as to the suppression of aggressive autoimmune reactions, reducing the risk of allergopathology development.

References

Varlamova T.V., Dorshakova N.V., Karapetyan T.A. Viruses as cofactors in the process of autoimmune distolerance. Obscaya biologia 2016; 8 (161): 14-19.

Vikulov G.Kh., Voznesenskiy S.L., Frolkin D.I. HPV- and herpes virus infections: epidemiological, pathogenetic and clinical immunological aspects, principles of diagnosis and therapy. Akusherstvo, Ginekologia i Reprodukcia 2020;14(1):102-111. https://doi.org/10.17749/2313-7347.2020.14.1.102-111

Belov B.S., Shubin S.V., Ananyeva L.P. Rational use of antibiotics in rheumatology. Sovremennaya revmatologia 2012; 2: 7-15. https://doi.org/10.14412/1996-7012-2012-722

Dyudyun A.D., Polion N.N., Nagorny A.E. Herpesvirus infection. Clinical and immunological features. Clinical lecture. Dermatovenerologia. Cosmetologia. Sexopathologia 2015; 3-4: 119-142.

Dyachenko P.A. Immune response to HSV infection and the causes of virus persistence. Klinicna imunologia.Alergologia.Infektologia 2011; 5: 26-28.

Kazmirchuk V.Y., Maltsev D.V. Modern view on the etiology, pathogenesis and treatment of autoimmune diseases. Klinicna imunologia. Alergologia. Infektologia 2009; 4 (23): 5-1.

Nedel'ska S.M., Mazur V.I., Shumna T.Y. Differential diagnosis of systemic connective tissue diseases and systemic vasculitis in children (navcalnyi posibnyk). Zaporizhya: ZDMU 2018; 1-114.

Chopyak V.V., Potomkina G.O., Lishchuk-Yakymovych Kh.O., that іnsh. Systemic connective tissue diseases: work experience. Ukrainskyi revmatologicnyi zurnal 2009; 2 (36): 15-21.

Shmiga T.V., Pukalyak R.M., Gaievska V.Yu., Gaievs'kiy V.Yu. Іnfektsіynі khvoroby 2016; 4 (86): 40-45. https://doi.org/10.4310/ICCM.2016.v4.n1.a5

Lu L., H. Cantor Generation and regulation of CD8+ regulatory T cells . Cell. Mol. Immunol. 2008; 6: 401-406. https://doi.org/10.1038/cmi.2008.50

Nandakumar S., Woolard S. N., Yuan D. [et al.] Natural killer cells as novel helpers in anti-herpes simplex virus immune response. J. Virol. 2008; 82(21):10820 - 10831. https://doi.org/10.1128/JVI.00365-08

Schleinitz N. Vely F., Harle J.N [et al.] Natural killer cells in human autoimmune diseases. Immunology 2010;131(4):451-458. https://doi.org/10.1111/j.1365-2567.2010.03360.x

Shevach E.M. Regulatory T cells in autoimmunity. Annu. Rev. Immunol. 2000; 18:423-449. https://doi.org/10.1146/annurev.immunol.18.1.423

White D.W., Beard R.S., Barton E. S. Immune modulation during latent herpesvirus infection. Immunol. Rev. 2012; 245:189 -208. https://doi.org/10.1111/j.1600-065X.2011.01074.x

Veetil B.M., Myasoedova E, Matteson E.L., et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013; 65(6):854-61. doi: 10.1002/acr.21928]. https://doi.org/10.1002/acr.21928

Published
2020-09-30
How to Cite
Gaiduchok, I., & Lishchuk-Yakymovych, K. (2020). Management of patients with systemic autoimmune diseases with the active phase of chronic herpes simplex infection. Acta Medica Leopoliensia, 26(2-3), 21-27. https://doi.org/10.25040/aml2020.02-03.021